ResearcherFudan UniversityNo recent work listed
Tianyu Li
Matched on ORCID iD 0000-0003-2166-0692; OpenAlex author ID A5100379458. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 2
2020: 1 paper · 2021: 1 paper
Papers 2
- Co-treatment With Everolimus, an mTOR-Specific Antagonist, or Downregulation of ELK1 Enhances the Sensitivity of Pancreatic Cancer Cells to Genistein. Co-author DOI 10.3389/fcell.2021.633035↗
- Comprehensive Analysis of Immunoinhibitors Identifies LGALS9 and TGFBR1 as Potential Prognostic Biomarkers for Pancreatic Cancer. First author DOI 10.1155/2020/6138039↗
Closest collaborators
The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yue Fan · 2 shared papers, 2020–2021 · strength 0.32
- Paper Comprehensive Analysis of Immunoinhibitors Identifies LGALS9 and TGFBR1 as Potential Prognostic Biomarkers for Pancreat… DOI 10.1155/2020/6138039↗
- Paper Co-treatment With Everolimus, an mTOR-Specific Antagonist, or Downregulation of ELK1 Enhances the Sensitivity of Pancre… DOI 10.3389/fcell.2021.633035↗
- Tiantao Kuang · 2 shared papers, 2020–2021 · strength 0.32
- Paper Comprehensive Analysis of Immunoinhibitors Identifies LGALS9 and TGFBR1 as Potential Prognostic Biomarkers for Pancreat… DOI 10.1155/2020/6138039↗
- Paper Co-treatment With Everolimus, an mTOR-Specific Antagonist, or Downregulation of ELK1 Enhances the Sensitivity of Pancre… DOI 10.3389/fcell.2021.633035↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.